| Literature DB >> 35116994 |
Shuyu Zhai1, Zhen Huo1, Yue Wang1, Hao Qian1, Shulin Zhao1, Yusheng Shi1, Yuanchi Weng1, Xiaxing Deng1, Baiyong Shen1.
Abstract
BACKGROUND: Pancreatic cancer is a highly aggressive cancer featured by early metastasis and multiple chemoresistance. Surgical resection remains the only way for the radical cure of pancreatic cancer. The aim of this study was to assess the safety, feasibility and oncological effect of the Heidelberg TRIANGLE operation in total pancreatectomy (TP) for borderline resectable pancreatic cancer (BRPC).Entities:
Keywords: Pancreatic cancer; general surgery; pancreatectomy
Year: 2019 PMID: 35116994 PMCID: PMC8798168 DOI: 10.21037/tcr.2019.09.50
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1CT scan of patients eligible for TRIANGLE operation.
Figure 2Pictures taken during surgery. The triangle indicates CA, SMA and PV/SMV, which are involved in TRIANGLE operation. CA, celiac axis; SMA, superior mesenteric artery; SMV, superior mesenteric vein; PV, portal vein.
Baseline parameters
| Characteristics | Number |
|---|---|
| Age | 63.33±10.1 |
| Sex (M/F) | 7:2 |
| BMI | 21.57±2.568 |
| ASA class ≤2 | 9 |
| ECOG ≤1 | 9 |
| Diabetes mellitus | 4 |
| Hypertension | 3 |
| Cardiopulmonary dysfunction | 0 |
BMI, body mass index; ASA, American Society of Anesthesiologist; ECOG, Eastern Cooperative Oncology Group.
Perioperative and pathological data
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Vascular invasion | SMA/SMV | SMV/PV | SMV/PV | SMV/PV/SV | CA/PV/PA | SMA/PV | SMA/PV | SMV/PV | PV/SMA |
| Surgery | One-step TP | One-step TP | One-step TP | One-step TP | One-step TP | One-step TP | One-step TP | One-step TP | Remnant TP |
| Operating time (min) | 240 | 420 | 660 | 200 | 420 | 300 | 550 | 240 | 420 |
| Blood loss (mL) | 200 | 300 | 1,500 | 600 | 400 | 500 | 800 | 200 | 1,200 |
| Reoperation | No | No | No | No | No | Yes | No | No | No |
| Pathological classification | PDAC | PDAC | PDAC | PDAC | IPMT | PDAC | IPMT | PDAC | PDAC |
| Tumor size (cm) | 8.1 | 8.4 | 6.1 | 3.8 | 13.5 | 3.5 | 8.6 | 5.6 | 4.2 |
| LNR | 2/22 | 4/39 | 7/38 | 7/24 | 4/19 | 2/35 | 2/27 | 10/44 | 3/22 |
| Margin | R0 | R0 | R0 | R0 | R0 | R0 | R1 | R0 | R0 |
| Perineuronal invasion | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| TNM stage (AJCC 8th) | III | III | III | III | III | III | III | III | III |
| Vein resection and reconstruction | PV | PV | PV | PV | PV | PV | PV | ||
| Postoperative adjuvant therapy | TCM | GS | GS | GEM | GS | TCM | S-1 | GS | TCM |
SMA, superior mesenteric artery; SMV, superior mesenteric vein; PV, portal vein; SV, splenic vein; CA, celiac axis; PDAC, pancreatic ductal adenocarcinoma; IPMT, intraductal papillary mucinous tumor; LNR, lymph node ratio; AJCC, The American Joint Committee on Cancer. GEM, Gemcitabine, 1,000 mg/m2 (i.v.) at 1st, 8th, 15th day of chemotherapy; GS, Gemcitabine + S-1, 1,000 mg/m2 gemcitabine (i.v.) at 1st,8th day of chemotherapy and 60 mg/m2 S-1 (po, bid) from 1st to 14th day of chemotherapy; S-1, 60 mg/m2 S-1 (po, bid) from 1st to 14th day of chemotherapy.
Figure 3Perioperative data collected in recent years and in TRIANGLE operation. (A) Operating time, (B) blood loss, (C) lymph node number and (D) number of positive lymph node.
Postoperative outcomes
| Characteristics | Number |
|---|---|
| Postoperative stay | 29 [17–42] |
| Abnormal blood sugar after medication | 0 |
| Diarrhea | 2 |
| POPF | 0 |
| PPH | 0 |
| Hypokalemia | 0 |
| Lymphatic leak | 2 |
| Biliary fistula | 1 |
| Reoperation | 1 |
| Colon fistula | 1 |
POPF, postoperative pancreatic fistula; PPH, postoperative hemorrhage.